戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ile, and a slightly long-lasting effect than triamcinolone acetonide.
2 a potentiating effect on the cytotoxicity of triamcinolone acetonide.
3 on of xylocaine alone or in combination with triamcinolone acetonide.
4  bone loss and who were treated with inhaled triamcinolone acetonide (100 microg per puff).
5 ons (9453 ranibizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were rev
6 viability of ARPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without th
7                     The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehi
8 dophthalmitis per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and
9               Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci
10 intervention: Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci
11 d with the chaperones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the rec
12 andomly allocated to receive an injection of triamcinolone acetonide, 40 mg, either IM in the ipsilat
13 week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day).
14                            They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice dail
15  two trans-Tenon's retrobulbar injections of triamcinolone acetonide after explaining the procedure a
16 aser may be more effective than intravitreal triamcinolone acetonide alone.
17       Topical therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorti
18 uided intra-articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine hydrochlor
19 ization was improved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients
20                                 Intravitreal triamcinolone acetonide and the IDI were superior to PTA
21 ent with inhaled albuterol and intramuscular triamcinolone acetonide and yearly for 5 years.
22  corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) rang
23 e Flt23k nanoparticles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subcon
24 (GCs) dexamethasone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to
25 PVD) confirmed by intraoperative findings of triamcinolone acetonide-assisted pars plana vitrectomy (
26  corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cro
27 to -6), response to a characterizing dose of triamcinolone acetonide (B, -8.4 mL/1% change FEV(1) pos
28 hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively
29  collected at baseline, after intramuscular (triamcinolone acetonide) corticosteroid treatment, and a
30                               The effects of triamcinolone acetonide cream 0.025% were assessed based
31 ant Q642V, which has an altered affinity for triamcinolone acetonide, dexamethasone, and corticostero
32 sion of ACE2 and TMPRSS2, but treatment with triamcinolone acetonide did not decrease expression of e
33         This study compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Te
34                       Treatment with topical triamcinolone acetonide dramatically reduced pathology b
35 hma receiving beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run
36 cts of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of
37              Four synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobeta
38                                 Intravitreal triamcinolone acetonide followed by laser may be more ef
39 tained-release suspension releasing 5-FU and triamcinolone acetonide for 1 month.
40  50, 100, and 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.
41 ty and efficacy of suprachoroidally injected triamcinolone acetonide formulation (CLS-TA), a suspensi
42 retical model predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's s
43                                       In the triamcinolone acetonide group, 12 months after surgery t
44  and sustainably released the corticosteroid triamcinolone acetonide in a rat model of patellar tendo
45 us); Protocol I (Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photoc
46 th intravitreal injections of bevacizumab or triamcinolone acetonide in patients with macular edema a
47 tonide formulation (CLS-TA), a suspension of triamcinolone acetonide, in improving vision among patie
48                                 In contrast, triamcinolone acetonide-induced luciferase activity was
49 hanges following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA),
50 ity after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprac
51 oroidal CLS-TA (proprietary formulation of a triamcinolone acetonide injectable suspension), and 64 r
52 e comparative study showed that intravitreal triamcinolone acetonide injection and the dexamethasone
53 l ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation.
54 effectiveness superior to that of periocular triamcinolone acetonide injection for these outcomes.
55 ion group, phacoemulsification with subtenon Triamcinolone acetonide injection group and phacoemulsif
56                  Intraoperative intravitreal triamcinolone acetonide injection induces earlier and ma
57  endolaser photocoagulation and intravitreal triamcinolone acetonide injection resulted in a complete
58                                 Intravitreal triamcinolone acetonide injection therapy, in particular
59 , 3 days, and 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls witho
60 periocular, suprachoroidal, and intravitreal triamcinolone acetonide injections and intravitreal dexa
61  received bevacizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexam
62 e suggested beneficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supple
63                                              Triamcinolone acetonide is toxic to proliferating cells
64 l retinal thickness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edem
65 ss the efficacy of intravitreal injection of triamcinolone acetonide IVTA combined with standard phac
66                                 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment
67 usion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing
68                      In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 wee
69  surface of the plate, and 20 mg of subtenon triamcinolone acetonide (Kenalog, Bristol-Myers Squibb)
70 ne the human biodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated an
71 n after posterior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted
72         The theoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreo
73 tocol, and swollen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month)
74                                 Intravitreal triamcinolone acetonide may be more effective than laser
75 itreal injections of ranibizumab or subtenon triamcinolone acetonide may prevent further progression
76  CT-guided TMJ injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexace
77 ns were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (
78 rectomy and ILM peeling assisted with either triamcinolone acetonide or infracyanine green staining i
79 ular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these thera
80                                 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral pro
81                                 Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard r
82 ceived an average of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 mont
83 ate the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevaciz
84  combined use of suprachoroidal injection of triamcinolone acetonide (SCTA) using a modified custom n
85                                     However, triamcinolone acetonide staining is associated with an i
86       Random assignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 session
87 and durability advantages of investigational triamcinolone acetonide suspension (CLS-TA; Clearside Bi
88                      Sedimentation of 1.0 mL triamcinolone acetonide suspension for intravitreal use
89 aoperative subconjunctival injection of 2 mg triamcinolone acetonide (TA) alone.
90 GR in complex with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small
91 culation on transscleral drug delivery using triamcinolone acetonide (TA) as a model drug.
92 racterize the safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique
93 ion of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transa
94  the posterior suprachoroidal placement of a triamcinolone acetonide (TA) suspension.
95 cy and safety of suprachoroidal injection of Triamcinolone Acetonide (TA) using a microinjector as a
96 At present, intralesional multi-injection of triamcinolone acetonide (TA) using a syringe is one of t
97   A novel conjugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using gluta
98 ating agents dexamethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize pro
99      Three agents-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial
100 ty guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors
101 dard topical corticosteroid (TCS) treatment, triamcinolone acetonide (TA), on the formation, maintena
102 treated with 100 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.
103 oid receptor (GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.
104  The inherent electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were
105                                              Triamcinolone acetonide (TAA) is an anti-inflammatory st
106                 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatme
107 , M: 770 microg, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 micr
108  properties of the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ion
109 ed this method to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma followi
110                                              Triamcinolone acetonide, the most commonly used intravit
111 bits received a subconjunctival injection of triamcinolone acetonide to one eye.
112 formulations encapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneo
113 uced cataract was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).
114 sion was documented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal
115 ith 14 days pre-treatment with INCS (220 mug triamcinolone acetonide twice daily).
116               In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD
117                            Carbon-11-labeled triamcinolone acetonide was formulated as the commercial
118 vehicle and with the vehicle alone, in which triamcinolone acetonide was suspended.
119 rong cytochrome P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced do
120 ning to glaucoma in response to intravitreal triamcinolone acetonide will be reviewed.
121  the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in
122 (>/=24 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.
123 duction when the R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for
124 y of ARPE-19 and R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 2
125                                              Triamcinolone acetonide with vehicle caused a greater re
126  in the ARPE-19 cells when treated with both triamcinolone acetonide, with or without the vehicle at
127 he patient underwent periocular injection of triamcinolone acetonide, with resolution of the subretin
128 ial dehydrogenase activity when treated with triamcinolone acetonide without the vehicle at any of th

 
Page Top